Ranbezolid

Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria[1][2][3].

392659-38-0

RBx7644 (free base)

12352005

Antibiotic; Bacterial

Anti-infection

COVID-19-immunoregulation

Infection; Cardiovascular Disease

CC(NC[C@H]1CN(C2=CC=C(N3CCN(CC4=CC=C([N+]([O-])=O)O4)CC3)C(F)=C2)C(O1)=O)=O

C21H24FN5O6

461.44

[1]Kalia V, et al. Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob Agents Chemother. 2009 Apr;53 (4) :1427-33.|[2]Mathur T, et al. Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis. Int J Antimicrob Agents. 2013 Jan;41 (1) :36-40.|[3]Naruganahalli KS, et al. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats. Eur J Pharmacol. 2006 Sep 18;545 (2-3) :167-72.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19428/

Reference compound1

No Development Reported